Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database.

Blood cancer journal·2026
Same author

Realistic presentation of estimated propensity score in the causal directed acyclic graph-response to Kim.

International journal of epidemiology·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Cancer.

JAMA oncology·2025
Same author

Incorrect Conclusions From Misinterpreting Point Estimates and CIs.

JAMA ophthalmology·2025
Same author

Balancing scores and causal diagrams.

International journal of epidemiology·2025
Same author

Use of medroxyprogesterone acetate and risk of meningiomas: a comparative safety study.

Expert opinion on drug safety·2025

Related Experiment Videos

Association between glaucoma, glaucoma therapies, and erectile dysfunction.

Nawaaz A Nathoo1, Mahyar Etminan, Frederick S Mikelberg

  • 1Departments of *Ophthalmology and Visual Sciences ‡Medicine †Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

Journal of Glaucoma
|July 23, 2013
PubMed
Summary
This summary is machine-generated.

This study found a confirmed association between glaucoma and erectile dysfunction (ED), which is not explained by the use of topical beta-blockers (BB). Further research is needed to understand the exact cause of this link.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Urology
  • Clinical Epidemiology

Background:

  • Erectile dysfunction (ED) is a common condition with multifactorial causes.
  • Glaucoma is a progressive optic neuropathy often managed with topical medications.
  • The potential relationship between glaucoma and ED requires further investigation.

Purpose of the Study:

  • To investigate the association between glaucoma and ED.
  • To determine if topical beta-blocker (BB) use is a confounding factor in the glaucoma-ED relationship.

Main Methods:

  • A province-wide database analysis identified 1380 ED cases and 13,800 controls.
  • Conditional logistic regression estimated rate ratios for glaucoma diagnosis and topical BB use.
  • Adjustments were made for cardiovascular and metabolic risk factors.

Main Results:

  • Glaucoma diagnosis was associated with a 1.37-fold increased rate of ED (adjusted rate ratio).
  • Topical beta-blocker use within 30 days of ED diagnosis showed no significant association.
  • Topical ocular prostaglandin use was also not significantly associated with ED.

Conclusions:

  • An association between glaucoma and ED exists, independent of topical BB use.
  • Cardiovascular and metabolic risk factors were accounted for, but the exact nature of the association remains unclear.
  • Further research is warranted to elucidate the causal pathways between glaucoma and ED.